# > CYGNUS MATRIX AMNIOTIC MEMBRANE TISSUE ALLOGRAFT



#### **CHRONIC RIGHT HEEL ULCER CASE STUDY**

The patient is a 79-year-old male with a full-thickness diabetic foot ulcer in the medial/posterior heel, which had been existent for 18 months prior to the first application of CYGNUS® Matrix amniotic membrane tissue allograft. The wound was granulated, necrotic, macerated, and staged as a Wagner grade 3.

# > APPLICATION OF VIVEX® BIOLOGICS CYGNUS® MATRIX AMNION TISSUE ALLOGRAFT AND OUTCOME

CYGNUS Matrix amniotic membrane tissue allografts were applied to the full-thickness diabetic foot ulcer as a wound covering, providing protection while retaining endogenous growth factors.¹,² ADAPTIC™ Non-Adhesive Silicone Dressing, Steri Strips, and gauze were applied as a dressing.




**PRE-APPLICATION OF CYGNUS MATRIX** 

Wound Dimensions: 3cm L x 1cm W x 0.2cm D



AFTER 3<sup>RD</sup> APPLICATION OF CYGNUS MATRIX

Wound Dimensions: 1cm L x 1cm W x 0.2cm D



AFTER 1<sup>ST</sup> APPLICATION OF CYGNUS MATRIX

Wound Dimensions: 2.5cm L x 2cm W x 0.2cm D



AFTER 4TH APPLICATION **OF CYGNUS MATRIX** 

Wound Dimensions: 0.5cm L x 0.5cm W x 0.2cm D



AFTER 2<sup>ND</sup> APPLICATION OF CYGNUS MATRIX

Wound Dimensions: 1cm L x 1cm W x 0.2cm D



AFTER 5TH APPLICATION **OF CYGNUS MATRIX** 

Wound Dimensions: 0.5cm L x 0.5cm W x 0.1cm D



After 5 CYGNUS Matrix applications over the course of 7 weeks, the wound experienced complete closure.

The patient had previously been treated with traditional wound care and other products, such as collagen powder and a competitive cryopreserved placental membrane. These methods did not work. Utilizing CYGNUS Matrix closed a long-standing ulcer.

# >> CONCLUSION

This case study demonstrates the use of VIVEX CYGNUS Matrix amniotic membrane tissue allograft as a wound covering to help close a chronic full-thickness diabetic foot ulcer. The CYGNUS tissue allograft is easy to apply, is available in multiple sizes, and will conform to wounds.

## > CYGNUS MATRIX

CYGNUS Matrix is a multi-layer membrane allograft maintaining the amnion layer, its intermediate/spongy layer, and the chorion layer of the amniotic sac. VIVEX's Integrity Processing™ preserves the inherent properties of amniotic tissues, maintaining key extracellular matrix molecules, proteins, carbohydrates, collagen, growth factors, and cytokines.¹

### > SAFE AND TRUSTED PARTNER

VIVEX Biologics is a regenerative solutions company focused on patient care through the innovation of tissue-based therapies in Wound Care, Ortho-Fusion, and Interventional Pain. With more than 50 years of highly safe and effective operations, VIVEX aims to provide advanced regenerative solutions.

- · Amniotic tissue is recovered from healthy mothers at live births.
- · Amniotic tissue is handled and processed in accordance with both FDA regulations and AATB standards.
- · VIVEX maintains the trend of safely delivering over 2 million allografts with no disease transmission.

VIVEX has used reasonable efforts to provide accurate and complete information herein, but this information should not be construed as providing clinical advice, dictating reimbursement policy, or as a substitute for the judgment of a health care provider. It is the health care provider's responsibility to determine the appropriate treatment, codes, charges for services, and use of modifiers for services rendered and to submit coverage or reimbursement-related documentation.

This research study was designed to test a product manufactured by VIVEX. The physician leading this research study receives compensation from VIVEX for consulting services related to and unrelated to this study. If you would like more information, please contact a VIVEX representative.

- 1. Delcroix Gaetan J. R., et. al. "Preserving the Natural Regenerative Potential of Amniotic Membrane." VIVEX Biologics, 2017.
- 2. Niknejad, Hassan, et. al. "Properties of the Amniotic Membrane for Potential Use in Tissue Engineering." European Cells and Materials, 2008, vol. 15, pp. 88-89.

